Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis

Digestive Diseases and Sciences

Volumn 60, Issue 11, 2015, Pages 3318-3328

  Ferslew, Brian C ^a,b   Xie, Guoxiang ^c   Johnston, Curtis K ^a   Su, Mingming ^c   Stewart, Paul W ^d   Jia, Wei ^c   Brouwer, Kim L R ^a   Sidney Barritt, A ^e  

^a University of North Carolina   (United States)

^b THERAVANCE INC   (United States)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^d IL   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bile acid metabolome; Bile acids; Enterohepatic recirculation; Nonalcoholic steatohepatitis

Indexed keywords

ALKALINE PHOSPHATASE; BILE ACID; GLUCOSE; GLYCINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TAURINE; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILE ACID BLOOD LEVEL; BILE ACID METABOLISM; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIET RESTRICTION; DISEASE COURSE; FEMALE; GALLBLADDER CONTRACTION; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIPID DIET; LIQUID CHROMATOGRAPHY; LIVER BIOPSY; MALE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; DISCRIMINANT ANALYSIS; METABOLOMICS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; POSTPRANDIAL STATE; PROCEDURES; REGRESSION ANALYSIS; TIME;

ADULT; BILE ACIDS AND SALTS; BIOMARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; DISCRIMINANT ANALYSIS; FASTING; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; METABOLOMICS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; POSTPRANDIAL PERIOD; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 84945465558     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3776-8     Document Type: Article

References (40)

1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–1395.
2. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–1609.
3. Perez MJ, Briz O. Bile-acid-induced cell injury and protection. World J Gastroenterol. 2009;15:1677–1689.
4. Neuman MG, French SW, French BA, et al. Alcoholic and non-alcoholic steatohepatitis. Exp Mol Pathol. 2014;97:492–510.
5. Trottier J, Bialek A, Caron P, Straka RJ, Milkiewicz P, Barbier O. Profiling circulating and urinary bile acids in patients with biliary obstruction before and after biliary stenting. PLoS One. 2011;6:e22094.
6. Mouzaki M, Comelli EM, Arendt BM, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58:120–127.
7. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006;47:241–259.
8. Hofmann AF. Bile acids: the good, the bad, and the ugly. News Physiol Sci. 1999;14:24–29.
9. Jonker JW, Liddle C, Downes M. FXR and PXR: potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol. 2012;130:147–158.
10. Roberts RE, Glicksman C, Alaghband-Zadeh J, Sherwood RA, Akuji N, le Roux CW. The relationship between postprandial bile acid concentration, GLP-1, PYY and ghrelin. Clin Endocrinol. 2011;74:67–72.
11. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574–582.
12. Bechmann LP, Kocabayoglu P, Sowa JP, et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology. 2013;57:1394–1406.
13. Hardwick RN, Fisher CD, Canet MJ, Scheffer GL, Cherrington NJ. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos Biol Fate Chem. 2011;39:2395–2402.
14. Ferslew BC, Johnston CK, Tsakalozou E, et al. Altered morphine glucuronide and bile acid disposition in patients with non-alcoholic steatohepatitis. Clin Pharmacol Ther. 2015;97:419–427.
15. Jia X, Naito H, Yetti H, et al. Dysregulated bile acid synthesis, metabolism and excretion in a high fat-cholesterol diet-induced fibrotic steatohepatitis in rats. Dig Dis Sci. 2013;58:2212–2222.
16. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146:1513–1524.
17. Kakiyama G, Hylemon PB, Zhou H, et al. Colonic inflammation and secondary bile acids in alcoholic cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2014;306:G929–G937.
18. Kalhan SC, Guo L, Edmison J, et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metab Clin Exp. 2011;60:404–413.
19. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.
20. Stone BG, Ansel HJ, Peterson FJ, Gebhard RL. Gallbladder emptying stimuli in obese and normal-weight subjects. Hepatology. 1992;15:795–798.
21. Xie G, Wang Y, Wang X, et al. Profiling of serum bile acids in a healthy Chinese population using UPLC-MS/MS. J Proteome Res. 2015;14:850–859.
22. Trottier J, Bialek A, Caron P, et al. Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study. Dig Liver Dis. 2012;44:303–310.
23. Garcia-Canaveras JC, Donato MT, Castell JV, Lahoz A. Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. J Lipid Res. 2012;53:2231–2241.
24. Tanaka N, Matsubara T, Krausz KW, Patterson AD, Gonzalez FJ. Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology. 2012;56:118–129.
25. Aranha MM, Cortez-Pinto H, Costa A, et al. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol. 2008;20:519–525.
26. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72:137–174.
27. Lake AD, Novak P, Shipkova P, et al. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol Appl Pharmacol. 2013;268:132–140.
28. Inagaki T, Moschetta A, Lee YK, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA. 2006;103:3920–3925.
29. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10:167–177.
30. Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439:484–489.
31. Faubion WA, Guicciardi ME, Miyoshi H, et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Investig. 1999;103:137–145.
32. Rodrigues CM, Fan G, Wong PY, Kren BT, Steer CJ. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med. 1998;4:165–178.
33. Spivey JR, Bronk SF, Gores GJ. Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of ATP depletion and cytosolic free calcium. J Clin Investig. 1993;92:17–24.
34. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Investig. 1998;101:2790–2799.
35. Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H. Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res. 2005;589:47–65.
36. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;56:1384–1391.
37. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 2007;97:1005–1008.
38. Larsson SC, Wolk A. Obesity and the risk of gallbladder cancer: a meta-analysis. Br J Cancer. 2007;96:1457–1461.
39. Reddy BS, Narasawa T, Weisburger JH, Wynder EL. Promoting effect of sodium deoxycholate on colon adenocarcinomas in germfree rats. J Natl Cancer Inst. 1976;56:441–442.
40. Zhang Y, Hagedorn CH, Wang L. Role of nuclear receptor SHP in metabolism and cancer. Biochim Biophys Acta. 1812;2011:893–908.